
|Videos|May 12, 2016
The Long-Term Impact of Biosimilars on Specialty Pharmacy
Author(s)Lauren Santye, Assistant Editor
Grant E. Knowles, vice president of business development at Ardon Health, discusses how biosimilars may impact the high cost of specialty drugs.
Advertisement
Grant E. Knowles, vice president of business development at Ardon Health, discusses how biosimilars may impact the high cost of specialty drugs.
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves mFlusiva, the First mRNA-Based Influenza Vaccine
2
The Side Door We Could Close: A Pharmacy Perspective on Menopause, Access, and the Leadership Pipeline
3
Tirzepatide Cuts MACE Risk in Diabetes With Heart Disease
4
Study Reveals a Widening Gap Between Buprenorphine Prescribing and Dispensing
5


































































































